Bridging the Gap From Knowledge to Practice in Castration-Resistant Prostate Cancer

Reference List


20. de Bono JS, Hardy-Bessard AC, Kim CS, et al. Phase III non-inferiority study of cabazitaxel (C) 20 mg/m² (C20) versus 25 mg/m² (C25) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel (D). *J Clin Oncol.* 2016;34(Suppl):Abstr 5008.


